Catheter ablation works better than drugs for heart rhythm disorder



To find its target, all a protein needs to do is give quick squeezes as it moves along the DNA strand, suggests new research from The University of Arizona in Tucson. Scientists had thought DNA-binding proteins primarily used full-body hugs for accurate readings of the information coded in the DNA’s sequence. Even a protein known

Full Post: Just a little squeeze lets proteins assess DNA

Treating a common heart rhythm disorder by burning heart tissue with a catheter works dramatically better than drug treatments, a major international study has found.

One year after undergoing a treatment called catheter ablation, 75 percent of patients with an irregular heartbeat called atrial fibrillation were free of symptoms. By comparison, only 21 percent of those treated with drugs were symptom-free. Results were so convincing the trial was halted early.

The ablation group also scored significantly higher on a quality-of-life scale

The study included 159 patients at 19 centers, including 15 centers in the United States. Results were presented at the American Heart Association 2008 Scientific Sessions in New Orleans by lead researcher Dr. David Wilber, director of the Cardiovascular Institute at Loyola University Stritch School of Medicine in Maywood, Il.

Atrial fibrillation, often called A-Fib, is the most common form of irregular heartbeat. Electrical signals, which regulate the heartbeat, become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. Atrial fibrillation can lead to strokes and heart failure.

A-Fib patient Robin Drabant, 34, of Hanover Park, Il., said the condition once “made me feel like I was 90 years old with a failing heart.” She was on a maximum dose of an A-Fib medication, which caused fatigue. Despite the drug, she still had episodes almost every day, lasting from 10 seconds to an hour or longer. “I would lose my breath and could feel my heart racing and fluttering,” she said.

Wilber performed a catheter ablation on Drabant last May, and she no longer has A-Fib episodes. “I had great results,” she said.

A-Fib symptoms include heart palpitations, dizziness, fatigue, shortness of breath and fainting. “A lot of people are disabled,” Wilber said. “They have no energy. They can’t work. They have a very poor quality of life.”

More than 2 million Americans have atrial fibrillation, and there are about 160,000 new cases each year. The number is increasing, due in part to the aging population and the obesity epidemic.

Drugs such as beta blockers and calcium channel blockers can slow the heart rate during an A-Fib episode. Other drugs such as flecainide and propafenone can help maintain a normal rhythm. When drugs don’t work or produce unacceptable side effects, alternative treatments include a pacemaker, surgery and catheter ablation.

In the ablation procedure, an electrophysiologist destroys small areas of heart tissue that are responsible for the erratic electrical signals. A catheter (thin flexible tube) is guided through blood vessels to the heart. The tip of the catheter delivers radiofrequency energy that heats and destroys tissue. Possible adverse effects include irritation of the lining of the heart, fluid in the lungs or around the heart, bleeding, clots and stroke.

In the study, 103 patients with frequent episodes of atrial fibrillation were randomly assigned to undergo ablation and 56 similar patients were randomly assigned to receive drug therapy. All patients had experienced at least three episodes of atrial fibrillation during the previous six months and had failed at least one attempt to control the rhythm with drugs.

The study was funded by Biosense Webster, which makes the ThermoCool catheter used in the trial. Wilber is a consultant to the company.

The study was the largest to date to compare ablation to drug therapy for atrial fibrillation. Earlier studies involved single centers and smaller sample sizes, Wilber said. An additional study called CABANA is designed to determine whether ablation patients live longer than patients receiving medication. Researchers will follow about 3,000 patients for three years.

http://www.luhs.org/

Link




Women who have up to two alcoholic drinks per day do not appear to be at increased risk of atrial fibrillation (irregular heart beat), but drinking more than that amount is associated with a higher risk, according to a study in the December 3 issue of JAMA, the Journal of the American Medical Association. Studies

Full Post: Two alcoholic drinks per day not linked with higher risk of atrial fibrillation for women



A new study shows that atrial fibrillation - the most common form of sustained heart arrhythmia - can be caused in an unexpected way. Researchers report in the December 12th issue of the journal Cell, a Cell Press publication, the first evidence that a rare and particularly severe form of the disease stems from a

Full Post: New cause of atrial fibrillation found



Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo. The Phase III global study, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF TIMI 48),

Full Post: Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation



CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease. The ACORD (Angiogenesis for the treatment of CORonary heart Disease) trial will include four randomized, double-blind, placebo-controlled doses in approximately 120

Full Post: CardioVascular BioTherapeutics doses first patient in trial for severe coronary heart disease



UC San Diego Medical Center is currently enrolling patients in a Phase 2 clinical trial of an investigational drug for the treatment of advanced heart failure. The “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease,” or CUPID, study is evaluating a new gene-based therapy designed to stimulate production of an enzyme that

Full Post: Trial of investigational drug for treatment of advanced heart failure